Welcome to our dedicated page for Medtronic SEC filings (Ticker: MDT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The pacemakers, insulin pumps, and neurostimulators that power Medtronic’s reputation live inside millions of patients—and inside hundreds of dense SEC documents. Product recalls, FDA approvals, and global tax disclosures can stretch a single Medtronic annual report beyond 300 pages, leaving many investors asking ‘where do I find the real story?’
StockTitan answers that question the moment a document hits EDGAR. Our platform ingests every Medtronic 10-K, 10-Q, 8-K, and Form 4, then deploys AI-powered summaries so Medtronic SEC filings explained simply is more than a promise. Need Medtronic insider trading Form 4 transactions or a heads-up on director buys? Real-time alerts flag Medtronic Form 4 insider transactions real-time as they occur. Prefer big-picture context? AI pulls segment revenue and margin shifts straight from the latest Medtronic quarterly earnings report 10-Q filing and packages them into concise dashboards.
Dig deeper with one click: targeted tags guide you to R&D spend, international tax notes, and safety disclosures inside the Medtronic annual report 10-K simplified. Governance questions? The Medtronic proxy statement executive compensation view highlights pay-for-performance metrics, while Medtronic 8-K material events explained keeps you ahead of recalls or FDA warnings. Whether you’re comparing cash-flow trends, tracking Medtronic executive stock transactions Form 4, or seeking a fast Medtronic earnings report filing analysis, our AI delivers the clarity you need for confident decisions—understanding Medtronic SEC documents with AI has never been easier.
Medtronic announced a significant board expansion and appointment in an 8-K filing dated June 28, 2025. The Board of Directors increased from 10 to 11 members with the appointment of Dr. Joon Lee, effective June 18, 2025.
Key details of the appointment:
- Dr. Lee will serve on the Science and Technology Committee and the Compensation and Talent Committee
- Will receive standard non-employee director compensation including annual cash retainer and equity grants as outlined in the August 2024 proxy statement
- No special arrangements or understandings influenced the appointment
- No reportable transactions under Item 404(a) of Regulation S-K between Dr. Lee or immediate family and the company
The appointment was formally announced via press release on June 23, 2025. The filing was executed by Ivan K. Fong, Executive Vice President, General Counsel and Secretary.
Medtronic plc (MDT) has delivered a routine notice to the U.S. Securities and Exchange Commission stating that its Annual Report on Form 10-K for the fiscal year ended April 25, 2025, filed on June 20, 2025, contains disclosure made under Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 and Section 13(r) of the Exchange Act. The letter, signed by Vice President, Global Controller and Chief Accounting Officer Denise L. Blomquist, fulfills the statutory requirement to alert the SEC of any Iran-related activities discussed in the 10-K. No quantitative details or descriptions of the underlying transactions are provided in this notice, leaving investors to consult the full 10-K for specifics.
Medtronic filed its FY2025 10-K report, detailing operations across four major segments: Cardiovascular, Neuroscience, Medical Surgical, and Diabetes. The company maintains a strong international presence with significant operations in both US and international markets.
Key operational highlights include:
- Strategic focus on enterprise excellence and simplification restructuring programs
- Continued investment in research and development across all segments
- Notable divestiture of the Ventilator Product Line in February 2024
- Completion of the Renal Care Solutions/Mozarc transaction in April 2023
Financial structure includes various senior notes due between 2025-2053 with interest rates ranging from 0% to 4.15%. The company maintains a diversified debt portfolio in multiple currencies (USD, EUR, JPY). Significant emphasis on fair value measurements and risk management, particularly in Level 3 assets including revenue and product development milestones.
FAQ
What is the current stock price of Medtronic (MDT)?
What is the market cap of Medtronic (MDT)?
What is the core business of Medtronic?
How does Medtronic generate revenue?
What markets does Medtronic serve?
How does Medtronic maintain its competitive edge?
What role do partnerships play in Medtronic's strategy?
How is Medtronic positioned in the medical technology industry?
What types of products does Medtronic offer?
What distinguishes Medtronic's approach to innovation?
How does Medtronic address patient safety?
What is Medtronic's global impact on healthcare?
